熱門資訊> 正文
Inspire Medical重申更新的2025年指南
2025-08-27 05:03
- Inspire Medical Systems (NYSE:INSP) is reaffirming updated 2025 financial guidance it made earlier this month following its Q2 results.
- At that time, the maker of a sleep apnea treatment implant significantly cut its revenue and EPS expectations citing slower than expected uptake of its next-generation device, the Inspire V.
- Revenue guidance is projected at $900M-$910M, while diluted net income per share guidance is expected at $0.40 to $0.50. Consensus is, respectively, $904.45M and $0.86.
More on Inspire Medical Systems
- Inspire Medical: Hiccups For The Sleep Business
- Inspire Medical Systems, Inc. (INSP) Q2 2025 Earnings Call Transcript
- Inspire Medical Systems, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Inspire Medical Systems CFO departs
- Inspire Medical to effect up to $200M stock buyback program
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
